Reviewer’s report

Title: Phase II Study of the Combination Carboplatin plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients

Version: 3 Date: 14 December 2010

Reviewer: Sandro Pignata

Reviewer’s report:

This phase II study shows significant activity of carboplatin-celecoxib in platinum resistant ovarian cancer.

Minor essential revisions:

In the table 1 the interval from last platinum and the median PFS from first line is confounding and should be eliminated. The important data is the proportion of patients with primary resistance and secondary resistance (both less than 6 months from previous platinum or from a non platinum given in resistant patients) compared to partially sensitive (6-12 months). This data is clearly indicated in the table.

Data on response can be given overall and divided in resistant and partially sensitive patients. The finding of this subgroup analysis should be discussed to possibly giving a better understanding of the action of celecoxib according to the different platinum sensitivity status.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests